Depletion of EphA3 or EphA4 recovers the decreased ERK and Akt activation and lytic gene expression in RNF5 KO PEL cells. by Xiaojuan Li (351842)

SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

“…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”

Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation. by Arindam P. Ghosh (317870)

“…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”

Glucose-lowering efficacy. by Sungmin Kim (628527)

Subjects:

Clinical factors affecting renal response to dulaglutide. by Sungmin Kim (628527)

Subjects:

eGFR values and mean eGFR change after the use of dulaglutide. by Sungmin Kim (628527)

Subjects:

Normal cell death but decreased cell proliferation of in <i>MiR125a</i>^-/- neutrophils. by Yuting Qin (1950118)

Mutation of <i>talB</i> in BAI3 results in a decrease of virulence partially complemented by the induction of <i>OsERF#123</i>. by Tuan T. Tran (5335004)

The interaction between TLCYnV C4 and DRM2 decreases the methylation level of endogenous DRM2-targets genes in tobacco. by Yuzhen Mei (4730877)

Inactivation of Rb leads to decreased expression of MEG3 and re-expression inhibits proliferation in A549 cells. by Traci L. Kruer (3342425)

Overexpression of TNFAIP9 remitted the renal inflammation caused by 5/6 Nx in C57 mice. by Ying Chen (9697)

Subjects:

Overexpression of TNFAIP9 alleviated the renal fibrosis caused by 5/6 Nx in C57 mice. by Ying Chen (9697)

Subjects:

HRMECs treated with 3-Deazaneplanocin A (DZNep) chemical inhibitor demonstrated increased miR-200b and decreased VEGF expression. by Michael Anthony Ruiz (726055)

“…[NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM D-glucose + 0.05% DMSO, HG+DMSO = 25mM D-glucose + 0.05% DMSO, NG+DZNEP = 5mM D-glucose + 5μM DZNep, HG+DZNEP = 25mM + 5μM DZNep; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to β-actin for VEGF and U6 for miR-200b, expressed as a fold change of NG].…”

Overexpression of TNFAIP9 counteracted the renal damage caused by 5/6 Nx in C57 mice. by Ying Chen (9697)

Subjects:

MigC interacts with and decreases the activity of MurD. by Jeanette M. Critchlow (21553796)

NOX4 depletion decreases cAMP concentration and AQP2 expression in a phosphodiesterase-dependent manner in mpkCCD_cl4 cells. by Eric Féraille (513934)

Subjects:

The flavanone homoeriodictyol increases SGLT-1-mediated glucose uptake but decreases serotonin release in differentiated Caco-2 cells - Fig 3 by Barbara Lieder (3743008)

ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity-5 by Rodrigo A Fuentealba (77901)

“…<p><b>Copyright information:</b></p><p>Taken from "ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity"</p><p>http://www.molecularneurodegeneration.com/content/2/1/14</p><p>Molecular Neurodegeneration 2007;2():14-14.…”

A blue-shifted fluorescence donor increases fAP amplitude but exhibits a decreased SNR. A. by Ann E. Fink (312543)

OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts. by S. Di Matteo (6260417)

“…After 4 weeks, when the tumor size was approximately 100 mm³ (T₀) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”